Slide 1: Phase 2 Interim Data
Developing Breakthrough Biologics, Life-changing Medicines® Phase 2 Interim Data May 9, 2024 (Data Cut-off: April 12, 2024)
Slide 2: Legal Notices
2 Legal Notices The information in this slide deck is current as of May 9, 2024, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herei
Slide 3: TAMARACK mCRPC Phase 2 Study Design Summary
3 Experimental Arm A Vobramitamab duocarmazine 2.0 mg/kg Q4W Experimental Arm B Vobramitamab duocarmazine 2.7 mg/kg Q4W R 1:1 Patients Enrolled N=91 Primary Endpoint: rPFS Key Secondary Endpoints: AEs, PSA outcomes, ORR, DoR, SSEs, PK, ADA, nAb (a) Participants who received an additional taxane or s
Slide 4: Patient Flow
4 Patient Flow TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 (a) Excludes three dosed patients who were on original Androgen Receptor Axis-Targeted therapy control arm. These patients are excluded from any analyses in this presentation. 249 Patients Assessed for Eli
Slide 5: Baseline Patient Characteristics of ITT Population
5 Baseline Patient Characteristics of ITT Population ECOG=Eastern Cooperative Oncology Group; PSA=prostate-specific antigen; ARAT=Androgen Receptor Axis-Targeted therapy. Parameter Vobra Duo 2.0 mg/kg q4W (n=91) Vobra Duo 2.7 mg/kg q4W (n=90) All (n=181) Age, years Mean ± SD 70.3 ± 9.03 69.1 ± 8.94
Slide 6: Interim Summary of Prostate-Specific Antigen (PSA) Response
6 Interim Summary of Prostate-Specific Antigen (PSA) Response PSA response evaluable population Parameter Vobra Duo 2.0 mg/kg q4W (N=82) Vobra Duo 2.7 mg/kg q4W (N=71) Any ≥50% PSA Reduction, n (%) (95% CI) 41 (50.0%) (38.7 – 61.3) 36 (50.7%) (38.6 – 62.8) PSA Response (Confirmed ≥50% PSA Reduction)
Slide 7: Interim Summary of Tumor Response
7 Interim Summary of Tumor Response RECIST evaluable patients with measurable disease at baseline Parameter Vobra Duo 2.0 mg/kg q4W (N=45) Vobra Duo 2.7 mg/kg q4W (N=32) Confirmed Objective Response Rate (ORR) (CR+PR), n (%) (95% CI) 8 (17.8%) (8.0 – 32.1%) 8 (25.0%) (11.5 – 43.4%) Confirmed + Uncon
Slide 8: Best % Change from Baseline in PSA
8 Best % Change from Baseline in PSA (2.0 mg/kg q4W) PSA response evaluable population (n=82) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Summary: • Any ≥50% PSA reduction = 41 pts. (50.0%) • Confirmed ≥50% PSA reduction = 36 pts. (43.9%)
Slide 9: Best % Change from Baseline in PSA
9 Best % Change from Baseline in PSA (2.7 mg/kg q4W) PSA response evaluable population (n=71) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Summary: • Any ≥50% PSA reduction = 36 pts. (50.7%) • Confirmed ≥50% PSA reduction = 26 pts. (36.6%)
Slide 10: Best % Change from Baseline in Investigator-Assessed Tumor Size
10 Best % Change from Baseline in Investigator-Assessed Tumor Size (2.0 mg/kg q4W) RECIST evaluable patients with baseline and post-baseline target lesion measurements (n=44)(a) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Summary: • Confirmed ORR (CR+PR) = 8 (17.8
Slide 11: Best % Change from Baseline in Investigator-Assessed Tumor Size
11 Best % Change from Baseline in Investigator-Assessed Tumor Size (2.7 mg/kg q4W) RECIST evaluable patients with baseline and post-baseline target lesion measurements (n=30)(a) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Summary: • Confirmed ORR (CR+PR) = 8 (25.0
Slide 12: Interim Investigator-Assessed Tumor Response
12 Interim Investigator-Assessed Tumor Response (2.0 mg/kg q4W) RECIST evaluable patients with measurable disease at baseline (n=45) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Summary: Confirmed PR = 8 pts. (17.8%) Confirmed + Unconfirmed PR = 11 pts. (24.4%) Ong
Slide 13: Interim Investigator-Assessed Tumor Response
13 Interim Investigator-Assessed Tumor Response (2.7 mg/kg q4W) RECIST evaluable patients with measurable disease at baseline (n=32) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Summary: Confirmed CR/PR = 8 pts. (25.0%) Confirmed + Unconfirmed CR/PR = 14 pts. (43.8
Slide 14: Interim Overall Summary of Adverse Events
14 Interim Overall Summary of Adverse Events Safety population (n=176) Vobra Duo 2.0 mg/kg q4W (N=90) Vobra Duo 2.7 mg/kg q4W (N=86) All (N=176) Any TEAE 89 (98.9%) 86 (100%) 175 (99.4%) Study Treatment Related AE 87 (96.7%) 83 (96.5%) 170 (96.6%) TEAE with Severity Grade ≥3 49 (54.4%) 44 (51.2%) 93
Slide 15: Interim Treatment-Emergent Adverse Events (TEAE) ≥10% (Any Grade)
15 Interim Treatment-Emergent Adverse Events (TEAE) ≥10% (Any Grade) Safety population (n=176); Ranked by # All Grade events for 2.7 mg/kg cohort Vobra Duo 2.0 mg/kg q4W (n=90) Vobra Duo 2.7 mg/kg q4W (n=86) AE Preferred Term (MedDRA v26.1) All Grade Grade ≥3 All Grade Grade ≥3 Asthenia 42 (46.7%) 3
Slide 16: Interim Treatment-Emergent Adverse Events ≥10% (Any Grade)
16 Interim Treatment-Emergent Adverse Events(a) (TEAE) ≥10% (Any Grade) Safety population (n=176) TAMARACK Phase 2 Interim Data • May 9, 2024 • Data Cut-off Date: April 12, 2024 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 2.0 mg/kg q4W Arm 2.7 mg/kg q4W Arm (a) Adverse event preferred terms as per MedDR
Slide 17: Thank You!
17 Thank You! Jim Karrels – SVP, Chief Financial Officer 301-354-2681 | karrelsj@macrogenics.com Link to our latest presentations: http://ir.macrogenics.com/events.cfm www.macrogenics.com Investor Relations Inquiries: Business Development Inquiries: Eric Risser – Chief Operating Officer rissere@macr